Zydus Wellness

Q2 results today: Britannia, Inox, Zydus Wellness among 118 firms

Q2FY26 company results: Firms including Aurobindo Pharma, Muthoot Microfin, Delhivery, Blue Star, and Eureka Industries are also to release their July-September earnings reports today

Zydus Wellness hits new high on GST boost, zooms 35% in 1 month; here's why

Zydus Wellness stock has surged 75% from its 52-week low; Company has fixed Sept 18 as the Record Date for determining entitlement of equity shareholders for stock split from ₹10 to ₹2.

Zydus Wellness gains 4%, hits new 52-week high as Anand Rathi lifts target

At 12:20 PM, Zydus Wellness share price was trading 3.02 per cent higher at ₹2,321.85 per share. In comparison, BSE Sensex was trading 0.16 per cent higher at 80,282.55 levels.

Zydus Wellness shares gain 9% post first overseas acquisition; details here

Zydus Wellness shares rose 4 per cent after its subsidiary acquired the UK-based Comfort Click Ltd. (CCL) for GBP 239 million

Zydus Wellness Q1 results: Net profit declines 13.4% to ₹127.9 crore

Zydus Wellness Ltd on Wednesday reported a 13.4 per cent decline in its consolidated net profit at Rs 127.9 crore for the first quarter ended June 30, 2025, with some of its seasonal brands affected by shorter summer and unseasonal rains, besides higher expenses. The company had posted a consolidated net profit of Rs 147.7 crore in the corresponding quarter last fiscal, Zydus Wellness said in a regulatory filing. Consolidated total revenue from operations in the quarter under review stood at Rs 860.9 crore as against Rs 841 crore in the year-ago period, it added. Zydus Wellness, which has a range of brands, including Glucon-D, Nutralite, Complan, Sugar Free, Nycil and Everyuth Naturals, said the majority of its brands delivered gross margin expansion, underscoring portfolio strength. "The saliency of seasonal brands was temporarily impacted by shorter-than-usual summers and unseasonal rains," it added. Total expenses in the quarter under review were higher at Rs 718.6 crore as ...

Dividend stocks: These 23 stocks to go ex-date on July 11; do you own any?

Here is the complete list of stocks that will trade ex-dividend on July 11, along with their key details

Zydus Wellness shares rally 7% as PPFAS picks up stake post True North exit

Zydus Wellness shares rallied 7 per cent on Wednesday, after True North exited by divesting its entire 7.27 per cent stake

True North exits Zydus Wellness, sells 7.27% stake for ₹879 crore

Mumbai-based True North on Tuesday exited Zydus Wellness by divesting its entire 7.27 per cent stake in the company while PPFAS Mutual Fund acquired the shares for Rs 879 crore through an open market transaction. Private equity firm True North, through its affiliate Threpsi Care LLP, offloaded 46.27 lakh shares or 7.27 per cent stake in Zydus Wellness, as per the block deal on the National Stock Exchange (NSE). The shares were sold at an average price of Rs 1,900 apiece, taking the transaction value to Rs 879.15 crore. Meanwhile, Parag Parikh Financial Advisory Services (PPFAS) mutual fund purchased the shares. Shares of Zydus Wellness rose 1.16 per cent to close at Rs 1,935.60 apiece on the NSE. In August last year, True North's arm Threpsi Care LLP sold a 2.6 per cent stake in Zydus Wellness for Rs 374 crore. Prior to that, the private equity firm in December 2023 offloaded a 1.23 per cent stake in the company for Rs 127 crore. In a separate block deal on the NSE, TVS Motor Com

Zydus Wellness gains 3% after 4.6 million shares change hand in pre-open

Zydus Wellness share price rose 3 per cent after 4.6 million shares traded in block deal on NSE, according to data compiled by Bloomberg

Emami, HUL, ITC: Is early monsoon good news for FMCG stocks? Analysts weigh

Early monsoon could be beneficial to agri-related and/or staple-focussed FMCG companies, while it may hurt those FMCG players that are more skewed towards summer portfolios.

Zydus Wellness Q4 result: Profit rises 14.4% to Rs 171.9 cr on strong sales

Zydus Wellness Ltd on Monday reported a 14.4 per cent rise in consolidated net profit at Rs 171.9 crore in the fourth quarter ended March 31, 2025, driven by strong performance of its food and nutrition as well as personal care segments. The company had posted a consolidated net profit of Rs 150.3 crore in the same quarter of the previous fiscal. The board of the company has approved the sub-division of its stock with one equity share of face value of Rs 10 to be split into five equity shares of face value Rs 2 each, subject to shareholders' approval. Consolidated total revenue from operations in the fourth quarter stood at Rs 910.6 crore, as compared to Rs 778 crore in the year-ago period, Zydus Wellness Ltd said in a regulatory filing. Total expenses in the quarter under review were higher at Rs 740.5 crore, as compared to Rs 632.2 crore in the corresponding period a year ago. With the continued thrust on marketing initiatives, several key brands including Nutralite, Glucon-D, .

Zydus Lifesciences to develop world's first dual vaccine for typhoid

Typhoid and shigellosis remain serious public health threats, particularly in low-resource settings

Pharma sector can deliver 100 new drugs by 2047: Zydus chairman

Indian pharma industry is capable of delivering 100 new drugs by 2047 for global markets backed by enhanced research and development efforts, Zydus Lifesciences Chairman Pankaj R Patel said on Friday. Speaking at an event here, he stressed the need for innovation, capability building, and a focus on societal benefit. "I believe India can deliver 100 new chemical entities or new drugs to the world by 2047 and off course, it will require effort," Patel said while speaking at the SOUL leadership conclave 2025. He termed it a myth that drug discovery requires a billion dollars while emphasising that it is possible with the right approach. Patel also asserted that the people working in an organisation are the most valuable resource and pitched for an environment where people love to work. He also emphasised the evolving nature of leadership, highlighting the importance of humility, vision, and a global perspective. Patel also shared experiences, including the Prime Minister's proactiv

Zydus Wellness arm gets Rs 56.33 cr GST demand over Heinz IP rights deal

Zydus Wellness Ltd on Saturday said its wholly-owned arm has received a GST demand of Rs 56.33 crore, along with applicable interest and penalty from the tax authority. Zydus Wellness Products Ltd (ZWPL), a wholly-owned subsidiary company, has received an intimation from the Directorate General of Goods and Services Tax Intelligence, Surat Zonal Unit, alleging GST demand of Rs 56.33 crore, along with applicable interest and penalty, Zydus Wellness Ltd said in a regulatory filing. The intimation alleges that the GST was payable in relation to the acquisition of intellectual property rights from Heinz Italia S.P.A. by Heinz India Pvt Ltd, now merged with ZWPL, it added. "ZWPL believes that there is a strong merit in the case, and ZWPL is evaluating the next steps based on a detailed review of the intimation," the filing said. The period covered by the order relates to the pre-acquisition period prior to January 30, 2019, the filing said. Due to this order, there is no impact on ...

Zydus Wellness shares soar 3% on acquiring Naturell (India) for Rs 390 cr

The rise in the share price came after the company announced that it has acquired 100 per cent stake in Naturell (India) Private Limited (NIPL), including its wholly owned subsidiary, for Rs 390 crore

Zydus Wellness board approves acquisition of Naturell India for Rs 390 cr

Zydus Wellness on Wednesday said its board has approved the acquisition of Naturell (India), a maker of healthy snacks such as nutrition bars and protein chips, for Rs 390 crore. The company's board has approved entering into the share purchase agreement with the promoters and other shareholders of Naturell (India) Pvt Ltd to acquire 1,50,78,605 equity shares of Re 1 each, representing 100 per cent of the paid-up share capital, at a consideration of Rs 390 crore, it said in a regulatory filing. "We believe that this acquisition is an opportunity to expand our portfolio by investing in brands and products that resonates with our company's portfolio and today's health-conscious consumers," Zydus Wellness Chairman Sharvil Patel said. The acquisition represents a strategic addition to Zydus Wellness, perfectly aligning with the company's aspirations to expand within the consumer wellness space, he added. Vijay Uttarwar, founder of Naturell (India) said Zydus has a proven track record o

True North's arm Threpsi sells 2.6% stake in Zydus Wellness for Rs 374 cr

Private equity firm True North's arm Threpsi Care LLP on Tuesday divested a 2.6 per cent stake in Zydus Wellness for Rs 374 crore through an open market transaction, while Quant Mutual Fund picked up the stake in the consumer wellness company. According to the block deal data available on the National Stock Exchange (NSE), Threpsi Care LLP sold 17 lakh shares, amounting to a 2.67 per cent stake in Ahmedabad-based Zydus Wellness. The shares were disposed of at an average price of Rs 2,201.40 apiece, taking the transaction value to Rs 374.24 crore. After the share sale, Mumbai-based True North's stake in Zydus Wellness has reduced to 7.45 per cent from 10.12 per cent. These shares were acquired by Quant Mutual Fund at the same price. Shares of Zydus Wellness fell 0.16 per cent to close at Rs 2,220 per piece on the NSE. In December last year, True North through its arm Threpsi Care LLP divested a 1.23 per cent stake in Zydus Wellness for Rs 127 crore.

Zydus Wellness Q1 profit surges 33.78% amidst strong brand performance

The company's flagship brands, Glucon-D, Nycil, Everyuth Peel-off, and Scrub, continued to dominate their respective categories

Zydus Wellness stock jumps 5%; hits 2-year high on hopes of demand recovery

The management sees encouraging signs of industry recovery, with inflation stabilising and margins poised for improvement.

Zydus Wellness Q4 profit up 3.4%, driven by strong brand performance

For the full year of FY24, the company posted a 14 per cent Y-o-Y decline in PAT and the revenue grew by 3.2 per cent reaching Rs 266.9 crore and Rs 2,327.8 crore respectively